Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03276026 · ClinicalTrials.gov registry record · Phase 4
A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery
A Phase 4 study, sponsored by Virtua Health.
- Terminated
- Registry status
- Phase 4
- Development phase
- 68
- Enrollment target
NCT03276026 is a Phase 4 study that was terminated before completion, run by Virtua Health. The registered enrollment target is 68 participants.
The verdict
NCT03276026, a Phase 4 study, was terminated before completion, sponsored by Virtua Health.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 68 participants
- Enrollment target
Study Summary
The investigators will track bariatric patients who received sugammadex versus neostigmine in the post anesthesia care unit until discharge and assess their length of stay and possible nausea / vomiting / hypoxia episodes.
Interventions
- DRUG Sugammadex
- DRUG Neostigmine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2018-02-12 |
| Est. Completion | 2018-11-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03276026
The ClinicalTrials.gov registry entry for NCT03276026 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virtua Health, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sugammadex is the first listed.
NCT03276026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03276026 about?
NCT03276026 is a clinical study titled "A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery". The investigators will track bariatric patients who received sugammadex versus neostigmine in the post anesthesia care unit until discharge and assess their length of stay and possible nausea / vomiting / hypoxia episodes.
What is the current status of trial NCT03276026?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 68 participants. The study started on 2018-02-12. Estimated completion is 2018-11-08.
What interventions are being tested in trial NCT03276026?
The interventions under investigation include: Sugammadex (DRUG), Neostigmine (DRUG).
Who is sponsoring clinical trial NCT03276026?
This trial is sponsored by Virtua Health, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.